  www.impactaging.com

     AGING, April 2016, Vol 8 No 4

                                                                       Review 

Apoptosis as anticancer mechanism: function and dysfunction of its 
modulators and targeted therapeutic strategies     

Giuseppa Pistritto1, Daniela Trisciuoglio2, Claudia Ceci1, Alessia Garufi2,3,  and Gabriella D’Orazi2,3

1Department of Systems Medicine, University “Tor Vergata”, 00133 Rome, Italy 
2Department of Research, Advanced Diagnostics, and Technological Innovation, Regina Elena National Cancer 
Institute, 00158 Rome, Italy 
3Department of Medical Oral and Biotechnological Sciences, Tumor Biology Unit, University “G. d’Annunzio”, 
66013 Chieti, Italy 

Key words: apoptosis, defective apoptotic pathways, cancer, small molecules, miRNAs, p53 
Received: 01/04/16; Accepted: 03/08/16; Published: 03/27/16 
Correspondence to: Gabriella D’Orazi, MD/PhD;  Giuseppa Pistritto, MD/PhD;  E‐mail:  gabriella.dorazi@unich.it; 
pistritto@med.uniroma2.it 

Copyright:  Pistritto  et  al.  This  is  an  open‐access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited 

Abstract:  Apoptosis  is  a  form  of  programmed  cell  death  that  results  in  the  orderly  and  efficient  removal  of  damaged
cells, such as those resulting from DNA damage or during development. Apoptosis can be triggered by signals from within
the  cell,  such  as  genotoxic  stress,  or  by  extrinsic  signals,  such  as  the  binding  of  ligands  to  cell  surface  death  receptors.
Deregulation in apoptotic cell death machinery is an hallmark of cancer. Apoptosis alteration is responsible not only for
tumor development and progression but also for tumor resistance to therapies. Most anticancer drugs currently used in
clinical  oncology  exploit  the  intact  apoptotic  signaling  pathways  to  trigger  cancer  cell  death.  Thus,  defects  in  the  death
pathways  may  result  in  drug  resistance  so  limiting  the  efficacy  of  therapies.  Therefore,  a  better  understanding  of  the
apoptotic cell death signaling pathways may improve the efficacy of cancer therapy and bypass resistance. This review will
highlight  the  role  of  the  fundamental  regulators  of  apoptosis  and  how  their  deregulation,  including  activation  of  anti‐
apoptotic factors (i.e., Bcl‐2, Bcl‐xL, etc) or inactivation of pro‐apoptotic factors (i.e., p53 pathway) ends up in cancer cell
resistance to therapies. In addition, therapeutic strategies aimed at modulating apoptotic activity are briefly discussed. 

INTRODUCTION 

Apoptosis, 
is  finely 
the  programmed  cell  death, 
regulated  at  gene  level  resulting  in  the  orderly  and 
efficient  removal  of  damaged  cells  such  as  those 
following  DNA  damage  or  during 
occurring 
development  [1].  The  machinery  of  apoptosis 
is 
involves  many  signaling  pathways. 
complex  and 
Apoptosis  can  be  triggered  in  a  cell  through  either  the 
caspase-mediated  extrinsic  or  intrinsic  pathways.  Both 
pathways  converge  to  activate  the  effector  apoptotic 
caspases  resulting  ultimately  in  morphological  and 
biochemical  cellular  alterations,  characteristics  of 
apoptosis  [2].  Usually,  the  balance  between  the  pro-
apoptotic   and  anti-apoptotic  protein  regulators   is   a  

cell 

critical  key  point  to  determine  if  a  cell  undergoes 
apoptosis. The induction of apoptosis as result of DNA 
damage in precancerous lesions can remove potentially 
tumor  growth. 
thereby  blocking 
harmful  cells, 
Deregulation  of  this  death  process  is  associated  with 
unchecked 
and 
proliferation, 
progression  of  cancer  and  cancer  resistance  to  drug 
that  reason,  deregulation  of 
therapies  [3,4].  For 
apoptosis  is  considered  one  of  the  hallmarks  of  cancer 
[5].  Therapeutic  strategies  targeting  molecules  involved 
in  apoptotic  resistance 
therefore  represent  a  valid 
approach  to  be  pursued  in  order  to  restore  cancer  cells 
sensitivity to apoptosis and overcome the ineffectiveness 
of  the  treatments  [6,7].  This  article  focuses  on  the 
the 
mechanisms  of  apoptosis,  how  defects  along 

development 

www.impactaging.com 

            603                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
apoptotic pathway contribute to cancer development and 
drug resistance and, briefly, how apoptosis can be used as 
a vehicle of targeted treatment in cancer. 

Morphological and biochemical changes in apoptosis 

the 

in  phagocytosis  without 

From  the  morphological  point  of  view  apoptotic  cells 
show a characteristic cytoplasmic cell shrinkage, budding 
of  plasma  membrane,  membrane 
exposure  of 
phosphatidylserine  (PS)  on  extracellular  side,  chromatin 
condensation and DNA fragmentation [8,9]. The plasma 
membrane  is  intact  throughout  the  total  process.  The 
expression of PS in the outer layers of the cell membrane 
allows  early  recognition  of  dead  cells  by  macrophages, 
release  of 
resulting 
proinflammatory  cellular  components  [10].  At  the  later 
stage  of  apoptosis  some  of  the  morphological  features 
include  membrane  blebbing,  ultrastructural  modification 
of cytoplasmic organelles and loss of membrane integrity 
[11].  Usually  phagocytic  cells  engulf  apoptotic  cells 
before  apoptotic  bodies  occur  [12].  Apoptosis 
is 
primarily executed by a family of proteases known as the 
caspases  (cysteinyl,  aspartate-specific  proteases)  [13]. 
Caspases  are  central  to  the  mechanism  of  apoptosis  as 
they  are  both  the  initiators  (caspase-2,  -8,  -9  and  -10, 
primarily  responsible  for  the  beginning  of  the  apoptotic 
pathway)  and  the  executors  (caspase-3,  -6  and  -7, 
the  definite  cleavage  of  cellular 
responsible 
components) of cell death [14]. After being produced as 
inactive proteins (zymogens or pro-caspases), the initiator 
caspases auto-activate through auto-proteolysis, a process 
that is facilitated by their interaction with specific adapter 
molecules  [15].  Once  activated,  the  initiator  caspases 
cleave  off  the  executors  caspases  that  perform  critical 
cleavage  of  specific  cellular  substrates  resulting  in  the 
final  apoptotic  cell  death  [16].  This  caspases  activity  is 
responsible of the apoptotic hallmarks, such as chromatin 
condensation, plasma membrane asymmetry and cellular 
blebbing.  The  extensive  and  irreversible  proteolytic 
activity  mediated  by  executor  caspases  represents  the 
ultimate  outcome  of  both  the  extrinsic  and  the  intrinsic 
apoptotic  pathways  (see  below).  Thus,  both  pathways 
converge on caspases-3, 6, or -7 that allow disruption of 
DNA  and  cellular  components  inducing  the  typical 
morphological  changes  in  apoptosis  [17].  Of  note, 
caspases activity has been also extended to non-apoptotic 
functions 
cell  differentiation/maturation 
the  caspase  cascade  may  become 
suggesting 
activated  independently  of–  or  without  inducing-  an 
apoptotic cascade [18-20]. 

such 
that 

for 

as 

Extrinsic apoptotic pathway 

The  extrinsic  apoptotic  pathway  (death  receptor-
dependent) is initiated by the interaction of cell surface 

signalling 

[22].  The  more 

exposed  death  receptors,  belonging  to  the  superfamily 
of  tumor  necrosis  factor  receptor  (TNFR),  with  their 
respective  protein  TNF  family  ligands  [21].  Death 
receptors  are  structurally  defined  by  an  intracellular 
protein-protein  interaction  domain,  called  the  death 
domain (DD), which is critically involved in apoptosis-
broadly 
inducing 
characterized  signaling  systems  of  death  receptor-
ligands  include  TNFR1-TNFα,  FAS  (CD95,  APO-1)-
FasL,  TRAILR1  (DR4)-TRAIL,  TRAILR2  (DR5)-
its 
TRAIL.  Upon  death  receptor  stimulation  by 
corresponding  ligand,  the  same  receptor  undergoes 
oligomerization  and  a  conformational  change  to  reveal 
its  cytoplasmic  DD  to  support  homotypic  interactions 
with  other  DD-containing  proteins  [21].  The  role  of 
adapter  proteins  (FADD/TRADD)  is  to  sequester,  at 
level of this protein complex, the initiator pro-caspase-8 
and/or  -10  resulting  in  the  formation  of  the  so-called 
death-inducing  signaling  complex  (DISC),  increasing 
the  local  concentration  of  pro-caspase  and  promoting 
the  mutual  auto-activation  [23].  The  activation  of 
initiator  caspases  results  in  the  processing  of  the 
downstream  effector  caspases-3,  -6  and  -7  whose 
activation  leads  to  the  cleavage  of  essential  substrates 
for  cell  viability,  inducing  cell  death  (Figure  1)  [17]. 
Some  cells  do  not  die  in  response  to  the  extrinsic 
pathway alone and require an amplification step that is 
induced by caspase-8. In this situation, capase-8 targets 
the  BH3-only  protein  Bid  (BH3-interacting-domain 
death  agonist)  for  cleavage  and  generate  the  activated 
fragment  t-Bid;  t-Bid  then  directly  activates  pro-
induce 
apoptotic  multi-domain 
mitochondrial  outer  membrane  permeability  (MOMP), 
so  this  co-engages  the  intrinsic  pathway  [3]  (Figure  1) 
(see below). 

proteins 

to 

Intrinsic apoptotic pathway 

intrinsic 

The 
(mitochondria-
apoptotic  pathway 
dependent)  is  mediated  by  intracellular  signals  that 
converge  at  the  mitochondrial  level  in  response  to 
different  stress  conditions  (i..e,  irradiation,  treatment 
with  chemotherapeutic  agents,  etc.)  [24].  Internal 
stimuli  such  as  irreparable  genetic  damage,  hypoxia, 
extremely  high  concentrations  of  cytosolic  Ca+  and 
severe oxidative stress are some triggers of the initiation 
of the intrinsic mitochondrial pathway [25]. Subsequent 
activation  of  pro-apoptotic  BH3-only  members  of  the 
Bcl-2  family  (Bax,  Bak)  neutralizes  the  antiapoptotic 
proteins Bcl-2, Bcl-xL, and Mcl-1, leading to disruption 
outer  membrane 
of  mitochondrial  membrane 
permeability 
that  proteins  normally 
confined  in  the  intermembrane  space  spread  into  the 
cytosol.  These  proteins  include  the  so-called  apopto-
genic  factors,  such  as  cytochrome-c,  which  plays  a 

(MOMP)  so 

www.impactaging.com 

           604                                           AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
crucial  role  in  activating  the  mitochondrial-dependent 
death  in  the  cytosol  [26].  Cytochrome-c  binds  to  the 
cytosolic Apaf-1 (apoptosis protease activating factor-1) 
and  triggers  the  formation  of  a  complex  named 
apoptosome, which recruits initiator pro-caspase-9 to its 
caspase  recruitment  domain  (CARD),  allowing  auto-
activation  and  then  proteolysis.  The  process  in  turn 
activates downstream executor caspases-3, -6 and -7 for 
cleavage of  cellular  substrates  leading  to  apoptotic cell 
death (Figure 1) [27,28]. 

The B-cell lymphoma 2 (Bcl-2) family proteins 

The intrinsic pathway is closely regulated by the B-cell 
lymphoma  2  (Bcl-2)  family  of  intracellular  proteins. 
This  proteins  family  regulates  both  pro-apoptotic  and 
anti-apoptotic 
the 
alteration of MOMP [29]. Therefore, by  mediating  per- 

intrinsic  pathways  controlling 

required 

meabilization of the mitochondrial membrane, the Bcl-2 
proteins serve as an “apoptotic switch” [30]. The Bcl-2 
proteins  are  classified  into  three  subgroups,  one  group 
with anti-apoptotic and two with pro-apoptotic function, 
depending  on  the  composition  of  typical  BH  (Bcl-2 
Homology)  domains,  listed  from  BH1  to  BH4  [31,32] 
(Figure 2). Whereas the BH1 and BH2 domains of bcl-2 
are 
for  dimerization  with  pro-apoptotic 
proteins,  BH3  domain  is  crucially  important  to  the 
interaction  between  pro-apoptotic  and  anti-apoptotic 
proteins  and  is  contained  by  all  family  members.  The 
amino-terminal BH4 domain is mainly found in the bcl-
2 family members with death-repressing activity, but is 
also present in some pro-apoptotic molecules. The anti-
apoptotic  multi-domain  group  includes  Bcl-2,  Bcl-xL, 
Bcl-W, Mcl-1, A1, and Bcl-B, containing from three to 
four BH domains; the pro-apoptotic multi-domain group 
includes Bax, Bak and  Bok  proteins,  containing  three  

Figure  1.  Intrinsic  and  extrinsic  apoptotic  pathways.  The 
intrinsic
(mitochondrial) and the extrinsic (ligands/death receptors) cell death pathways
and their convergence through t‐Bid are depicted (see text for details). 

www.impactaging.com 

            605                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BH-domains  (BH1,  BH2  and  BH3);  and  the  pro-
apoptotic  BH3-only  proteins  group  includes  Bid  (BH3 
interacting-domain  death  agonist),  Bim  (Bcl-2-like 
protein  11),  Bad  (Bcl-2-associated  death  promoter), 
Puma  (p53  upregulated  modulator  of  apoptosis), 
Noxa, BMF, HRK and BIK (Figure 3) [33]. While the 
anti-apoptotic proteins regulate apoptosis by blocking 
the  mitochondrial  release  of  cytochrome-c,  the  pro-
apoptotic proteins act by promoting such release.  

The  balance  and  protein-protein  interactions  between 
Bcl-2 family members is required to determine whether 
a  cell  undergoes  cell  survival  or  apoptosis.  The 
activation  of  Bax  (cytosolic  protein  that  translocates 
into  mitochondria  during  induction  of  apoptosis),  and 
in 
Bak 
the 
located 
(integral  membrane  protein 
involves 
mitochondria  and  endoplasmic  reticulum) 
conformational  changes  that  trigger  the  formation  of 
homo-oligomeric protein complexes that end up altering  

Figure 2. Bcl‐2 family members domain composition and function. Typical BH (Bcl‐2
Homology) domains, listed from BH1 to BH4, are shown. TM: transmembrane domain. 

Figure  3.  Bcl‐2  protein  subgroups.  The  Bcl‐2  proteins  are  classified  into  three  subgroups,  one 
group with anti‐apoptotic and two with pro‐apoptotic function, depending on the composition of the 
typical BH domains, listed from BH1 to BH4. Representative members of each subfamily are shown. 

www.impactaging.com 

           606                                           AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the  mitochondrial  membrane  permeability  [34,35].  The 
pro-apoptotic  BH3-only  proteins  act  upstream  of  this 
event binding with high affinity to anti-apoptotic Bcl-2 
family  members  thereby  allowing  Bax/Bak  to  elicit 
MOMP  and  activation  of  the  caspase  cascade  [36,37]. 
Anti-apoptotic  multidomain  members  of  the  Bcl-2 
protein  family  not  only  counteract  the  pore-forming 
activity of Bax and Bak by engaging in direct inhibitory 
interactions,  but  also  prevent  the  generation  of  pro-
apoptotic  cytosolic  Ca2+  waves  either  by  reducing 
capacity  of  endoplasmic  reticulum  (ER)  Ca2+  storage, 
an  effect  that  is  antagonized  by  Bax  and  Bak  or  by 
interacting  with  inositol  1,4,5-  trisphosphate  (IP3) 
receptor  [38,39].  Other  apoptotic  factors  that  are 
released  from  the  mitochondrial  intermembrane  space 
into  the  cytoplasm  include  apoptosis  inducing  factor 
(AIF), second mitochondria-derived activator of caspase 
(Smac),  direct  IAP  Binding  protein  with  Low  pI 
(DIABLO)  and  Omi/high 
temperature  requirement 
protein A (HtrA2) [40]. 

The inhibitors of apoptosis proteins (IAPs) 

Considering  that  proteolysis  is  an  irreversible  process, 
strict control of caspases-mediated proteolytic cleavage 
is  imperative  to  prevent  inappropriate  cell  destruction 
[41].  Negative  regulation  of  caspases  function  is 
achieved  by  IAP  proteins  family  whose  principal 
members 
in  humans  are  NAIP  (BIRC1),  cIAP1 
(BIRC2),  cIAP2  (BIRC3),  X-linked  IAP  (XIAP, 
BIRC4), Survivin (BIRC5), Apollon (BRUCE, BIRC6), 
Livin/ML-IAP (BIRC7), and IAP-like protein 2 (ILP2 – 
BIRC8) [42]. Their characteristic BIR (baculovirus IAP 
repeat)  domain  mediates  the  interaction  with  various 
proteins  and  gives  them  the  ability  to  bind  and 
inactivate  caspases  [43].  The  activities  of  IAPs, 
however, may be suppressed by mitochondrial proteins, 
such  as  Omi/HtrA2  and  Smac/DIABLO,  released  into 
the  cytosol  during  apoptosis 
(Figure  4).  These 
endogenous  IAPs  antagonists  are  able  to  bind  to  the 
BIR  domain  of  IAPs  reducing  their  ability  to  interact 
with  caspase-3  or  -9  thereby  restoring  their  activity 
[44].  XIAP  is  the  best  characterized  IAP  so  far  and  is 
generally  recognized  as  the  most  potent  endogenous 
caspase inhibitor. XIAP anti-apoptotic activity involves 
inhibition  of  active  executor  capsases  as  well  as 
prevention of initiator caspase-9 activation [45]. 

Alterations of the apoptotic pathways 

There are many ways through which both the extrinsic 
and  the  intrinsic  apoptotic  pathways  may  be  altered, 
resulting  in  reduction  of  apoptosis  or  acquisition  of 
apoptosis  resistance.  They  include  impaired  death 
receptor  signaling,  disrupted  balance  between  pro-
apoptotic  and  anti-apoptotic  proteins,  reduced  caspase 
impaired  p53  function  (Figure  5). 
function  and 
Alteration  of  extrinsic  apoptotic  signaling  has  been 
associated  with  different  types  of  human  tumors, 
underscoring  how  the  loss  of  activity  of  Fas-FasL 
system  [46]  or  the  aberrant  expression  of  cytosolic 
components  of  this  death  receptor  apoptotic  pathway 
(i.e.,  FADD)  [47]  can  contribute 
tumor 
transformation.  Several  genetic  defects  have  been 
proven  to  contribute  to  the  resistance  of  tumor  cells  to 
Fas-mediated apoptosis.  Fas  transcriptional  silencing  is 
a  common  oncogenic  event 
the  epithelial 
transformation,  while  its  mutation  has  been  often 
center-derived 
associated  with  B-cell  germinal 
lymphomas  [48].  In  acute  myelogenous 
leukemia 
(AML) reduced or absent expression of FADD has been 
frequently  observed, 
to 
chemotherapy  and  poor  patient  prognosis  [47,49]. 
Moreover,  in  several  cancers  including  neuroblastoma, 
medulloblastoma,  and  small  cell  lung  cancer  (SCLC), 
absent or reduced expression of caspase-8 was reported 

resistance 

resulting 

the 

in 

to 

in 

Figure  4.  Function  of  inhibitors  of  apoptosis
proteins  (IAPs).  IAPs  are  often  overexpressed  in
cancer and they have the ability to bind and inactivate
caspases  9  and  3.  The  activities  of  IAPs,  on  the  other
hand,  may  be  suppressed  by  mitochondrial  proteins,
such  as  Omi/HtrA2  and  Smac/DIABLO,  released  into
the cytosol during apoptosis. 

www.impactaging.com 

            607                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[50-52].  Another  resistance  mechanism  reported  in  a 
variety  of  human  tumors  is  the  overexpression  of  anti-
apoptotic  protein  c-Flip,  recruited  at  the  DISC  level, 
that  prevents  the  pro-caspase-8  auto-activation  thereby 
rendering  cell  resistant  to  death  receptor-mediated 
apoptosis [53-55]. 

As  for 
the  extrinsic  pathway,  alteration  of  some 
components of the intrinsic apoptotic pathway can play a 
fundamental  role  in  the  development  of  resistance  to 
chemotherapy in different types of tumors. Disruption in 
the balance of anti-apoptotic and pro-apoptotic members 
of the Bcl-2 family results in deregulated apoptosis in the 
affected cells. This can be due to overexpression of one 
or more anti-apoptotic proteins or downregulation of one 
or more pro-apoptotic proteins or a combination of both. 
Anti-apoptotic  Bcl-2  over-expression  has  been  reported 
in  several  human  cancers,  including  prostate  cancer, 
diffuse large B-cell lymphoma (DLBCL), melanoma, etc. 
[56-58],  resulting  in  protection  of  cancer  cells  from 
apoptosis  or  inhibition  of  TRAIL-induced  apoptosis 
[59,60]. Overexpression of Bcl-xL has also been reported 
in colorectal cancer and Kaposi's  sarcoma  [61,62].  Such  

overexpression confers a multi-drug resistance phenotype 
in  tumor  cells  and  prevents  them  from  undergoing 
apoptosis  [63].  Thus,  high  expression  levels  of  anti-
apoptotic  proteins  Bcl-2  and  Bcl-xL  have  been  reported 
to correlate with cisplatin resistance and tumor recurrence 
in different cancers including non-small cell lung cancer 
(NSCLC),  head  and  neck,  ovarian,  and  breast  [64-68]. 
On  the  other  hand,  mutations  in  the  pro-apoptotic  Bax 
gene  have  been  reported  in  colorectal  cancers  and 
contribute  to  resistance  to  anticancer  treatments  [69]. 
Increased  Bcl-2/Bax  ratio  has  been  reported  in  chronic 
lymphocytic  leukaemia  (CLL)  patients.  [70].  Other 
examples  of  alteration  of  the  intrinsic  pathway  include 
reduced  expression  of  the  basic  component  of  the 
apoptosome,  Apaf-1,  in  melanomas  [71,72],  as  result  of 
promoter  aberrant  methylation.  In  addition,  tumor  cells 
resistance to apoptosis also occurs as a result of alteration 
of mediators that control the intrinsic apoptotic pathway 
downstream  from  the  apoptosome  formation,  i.e.  acting 
on  caspase  activity.  In  this  regard,  high  level  of  IAPs 
expression  has  been  found  in  different  types  of  cancers, 
and  this  evidence  is  considered  a  marker  of  poor 
prognosis for patients [73,74]. 

Figure 5. Mechanisms leading to deregulation of apoptosis. Schematic representation
of  the  different  ways  through  which  both  the  extrinsic  and  the  intrinsic  apoptotic  pathways
may be altered, resulting in reduction of apoptosis or acquisition of apoptosis resistance. 

www.impactaging.com 

            608                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacological targeting of the apoptotic pathways 

apoptosis  may 

receptor-dependent 

this  evidence,  restoration  of  apoptotic 
Based  on 
pathway  by  drugs  targeting  both  apoptotic  pathways 
constitutes a promising anticancer therapeutic approach. 
Regarding  the  extrinsic  pathway,  the  down-regulation 
of  c-Flip  by  metabolic  inhibitors  and  the  promotion  of 
caspase-8  activation  by  interferon,  are  some  examples 
of  strategies  aimed  at  making  tumors  responsive  to 
death  receptor-induced  apoptosis,  and  more  generally, 
to  chemotherapy-induced  apoptosis  [55,75,76].  The 
therapeutic  importance  of  inducing  apoptosis  through 
the  extrinsic  pathway  also  extends  to  cancer  cells  that 
do  not  show  defects  in  components  of  that  pathway. 
Indeed,  inducing  the  apoptosis  by  stimulating  the 
extrinsic  pathway  can  overcome  the  resistance  to 
therapeutic agents that act by causing DNA damage, as 
death 
occur 
regardless  of  the  stress  response.  An  example  of  such 
therapeutic strategy is represented by the ligand TRAIL 
known to induce apoptosis in different tumor cell lines 
[77].  The  preferential  destructive  effect  against  tumor 
cells  and  the  apparent  absence  of  systemic  toxicity 
the 
through  TRAIL-induced 
development  of  antibodies  with  agonistic  activity 
against  the  TRAIL  death  receptors  (DR4  and  DR5)  or 
soluble recombinant derivatives of TRAIL (sTRAIL) as 
promising  chemotherapeutic  agents  [78].  An  attractive 
strategy  to  sensitize  resistant  malignancies  to  TRAIL-
induced cell death is the design of small molecules that 
target and promote caspase-8 activation. Through an in 
silico  screening  some  authors  successfully  found  a 
small  molecule 
[79]. 
Experimental  validation  performed  in  multiple  cell 
lines, such as leukemic and prostate cells, revealed that 
CaspPro small molecule promotes caspase-8 activation, 
caspase-3  activation  and  PARP  cleavage, 
the 
presence of TRAIL, leading to cell death [79]. Owing to 
its  different  toxicity  for  transformed  as  opposed  to 
normal  cells,  Apo2/TRAIL  shows  promise  as  potential 
cancer therapy agent [80,81]. 

apoptosis, 

caspase-8 

activator 

led 

of 

to 

in 

As  in  the  extrinsic  pathway,  mediators  of  the  intrinsic 
pathway  involved  both  in  tumorigenesis  and  chemo-
resistance,  are  targeted  for  therapeutic  approaches. 
These  anticancer  strategies  attempt  to  develop  drug-
designed  inhibitors  of  anti-apoptotic  proteins  typically 
overexpressed in cancer cells, such as Bcl-2, Bcl-xL and 
IAPs  [82].  Efforts  to  target  Bcl-2  proteins  involve  the 
development  of  agents  that  disrupt  Bcl-2  complexes. 
BH3  mimetics  bind  to  the  hydrophobic  groove  of 
antiapoptotic  proteins  mimicking  the  action  of  BH3-
only  proteins  in  binding  to  pro-survival  proteins, 
leading  to  the  release  of  BH3-only  proteins  from 
complexes  and  activation  of  BAX  and  BAK.  So  far, 

(venetoclax) 

nearly a dozen BH3 mimetics are under investigation as 
Bcl-2  inhibitors  in  different  phases  of  human  clinical 
trials  such  as  AT-101  (R-(-)-gossypol)  [83,84],  ABT-
199 
[86],  ABT-263 
[85],  ABT-737 
(navitoclax,  orally  available  derivative  of  ABT-737) 
[87,88], GX15-070 (obatoclax) [89,90] and TW37 [91]. 
The  field  of  inhibitors  of  Bcl-2  family  members  is  in 
continuous  development  [92,93],  underscoring 
the 
importance  of  these  molecules  as  potent  anticancer 
agents. Moreover, targeting the specific BH4 domain of 
Bcl-2 is also emerging as a novel strategy for anticancer 
therapy  [94].  Thus,  Bcl-2,  via 
its  BH4  domain, 
cooperates  with  numerous  proteins  regulating  different 
cellular  pathways  involved  in  tumor  progression  and 
chemoresistance such as hypoxia and angiogenesis [95-
97].  Recently,  a  small  molecule  namely  BDA-366  was 
discovered  as  a  potent  and  effective  BH4  domain 
antagonist, displaying remarkable anticancer activity in 
vitro and in vivo, thus providing the proof-of-concept of 
this  approach  [98].  Another  innovative  approach  to 
inhibit Bcl-2 comes from the evidence that human bcl-2 
gene  contains  a  GC-rich  sequence  located  in  its 
promoter  with  the  potential  to  form  G-quadruplex 
structures  [99]  and  functions  as  a  transcriptional 
repressor  element.  Therefore,  G-quadruplex-specific 
ligands  can  regulate  the  transcription  of  bcl-2  through 
stabilization of quadruplex structure [100,101]. 

the 

that 

in  part  by 

it  has  been  shown 
least 

tumor 
Interestingly, 
suppressor  p53,  at 
transcription 
independent  mechanisms,  contributes  to  cell  death 
induction  by  BH3  mimetic  inhibitors  of  BCL-xL.  In 
addition to mildly facilitating the ability of compounds 
to  derepress  BAX  from  BCL-xL,  p53  also  provides  a 
death  signal  downstream  of  anti-apoptotic  proteins 
inhibition that is independent from PUMA, as enhanced 
p53  can  substitute  for  PUMA  to  promote  BAX 
activation in response to BH3 mimetics [102]. It is thus 
of  particular  relevance  that  p53,  even  when  expressed 
constitutively  under  conditions  where  it  does  not 
influence 
pro-apoptotic 
transcription  targets,  enhances  cell  death  induced  by 
BCL-xL  inhibition  [102].  Such  results  suggest  on  one 
hand  that  BH3  mimetics  may  not  totally  substitute  for 
the  lack  of  an  active  p53  tumor  suppressor  in  cancer 
cells; on the other hand, they imply that healthy tissues 
may  be  more  harmed  than  anticipated  when  BCL-xL 
inhibitors  are  combined  with  chemotherapeutic  agents 
that even mildly affect p53. 

expression 

the 

its 

of 

Among  the  therapeutic  strategies  targeting  IAPs  two 
approaches  have  being  developed,  that  is  the  use  of 
antisense  oligonucleotides  and  of  small-molecule 
inhibitors.  The  XIAP  down-regulation 
through 
administration  of  antisense  agents  carried  by  an 

www.impactaging.com 

            609                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
adenoviral vector has been proven effective in inducing 
apoptosis  in  chemoresistant  ovarian  cancer  cells  [103] 
and  sensitizing  lung  cancer  cells  to  the  radiation 
treatment  [104].  Similarly,  the  inhibition  of  XIAP 
expression  with  specific  oligomers  has  been  shown  to 
induce  caspase-3  activity,  boosting  the  apoptotic  effect 
of  cisplatin  and  TRAIL  in  human  prostate  androgen-
insensitive  cancer  cells  [105].  Moreover,  preclinical 
studies  have  shown  that  Smac  mimetics  can  directly 
trigger  cancer  cell  death  or  sensitize  tumor  cells  to 
various  cytotoxic  therapies,  including  conventional 
chemotherapy,  radiotherapy,  or  novel  agents.  They 
promote  activation  of  caspases  by  neutralizing  XIAP-
mediated  caspase 
the 
success of each therapeutic strategy depends mainly on 
the  ability  of  the  therapeutic  tool  to  induce  apoptosis 
either  by  targeting  the  overexpressed  anti-apoptotic 
proteins  or  by  stimulating  the  expression  of  the  pro-
apoptotic molecules. 

inhibition  [106].  Therefore, 

However, it is worth to mention that the cancer genetic 
background  may  induce  failure  of  apoptosis  by  drugs. 
In  this  regard,  KRAS  and  the  PI3K/AKT/mTOR 
pathway  are  frequently  dysregulated  in  cancer  and,  for 
such  reason,  are  the  most  critical  targets  in  clinical 
oncology. Thus, direct targeting of KRAS has not been 
successful  so  far  and,  similarly,  inhibition  of  the 
PI3K/AKT/mTOR  pathway  often  results  in  apoptosis 
resistance.  Using  a  panel  of  20  human  KRAS-mutant 
NSCLC (non-small cell lung cancer) cell lines Hata and 
collaborators show that most human KRAS-mutant cell 
lines  fail  to  undergo  marked  apoptosis  in  response  to 
AZD6244  (Selumetinib,  a  potent,  selective,  and  ATP-
uncompetitive  inhibitor  of  MEK1/2  kinases)  [107]  in 
combination  with  GDC-0941  (an  orally  bioavailable 
inhibitor  of  class  I  PI3K)  [108],  thus  suggesting  that 
failure  to  induce  apoptosis  may  limit  the  efficacy  of 
combined MEK and PI3K inhibition for KRAS-mutant 
NSCLCs.  This  differential  apoptotic  response  induced 
by  MEKi/PI3Ki  is  not  simply  explained  by  variable 
inhibition  of  RAS  effector  pathways  but  results  from 
differential  ability  of  the  MEK  and  PI3K  pathways  to 
modulate  the  BCL-2  family  of  apoptotic  regulatory 
proteins [109]. Another recent study reveals that Bcl-xL 
upregulation  is  an  important  mechanism  of  apoptosis 
resistance in mutant KRAS cells. Concurrent induction 
of  pro-apoptotic  Noxa/Bik  and  antagonism  of  Bcl-xL 
have been shown to synergistically interact to overcome 
KRAS-mediated  apoptosis  resistance  [110].  These 
findings  highlight  a  promising  therapeutic  strategy  to 
overcome  apoptosis 
in  KRAS-mutant 
colorectal  cancer  cells.  Moreover,  Corcoran  and 
collaborators  identified,  by  a  pooled  shRNA-drug 
screen,  a  synthetic,  lethal  interaction  of  combined  Bcl-
xL and MEK inhibition to promote tumor regressions in 

resistance 

KRAS  mutant  cancer  models  [111].  Therefore,  a  dual-
targeted or multitargeted strategy may be more efficient 
to  overcome  the  resistance  due  to  cancer  genetic 
background. 

Oncosuppressor p53 and apoptosis 

receptor 

The tumor suppressor p53 is a transcription factor that, 
upon  DNA  damage,  is  activated  to  induce  sequence-
specific  target  genes  involved  in  either  cancer  cell 
growth  arrest  or  apoptosis  [112].  Activation  of  wild-
type  (wt)  p53  occurs  in  response  to  genotoxic  stress 
essentially through posttranslational modifications, such 
as acetylation and phosphorylation, resulting in protein 
stabilization  (by  escape  from  proteasome-mediated 
degradation) and nuclear localization leading to binding 
to  sequence-specific  promoters  of  target  genes  as  final 
outcome  of  its  function  as  transcription  factor  [113]. 
The  induction  of  apoptosis  by  p53  in  response  to 
cellular  stress  is  its  most  conserved  function  and  is 
crucial for p53 tumor suppression [114]. The apoptotic 
activation  of  p53  is  central  not  only  for  preventing 
tumor  transformation  but  also  for  efficient  response  to 
therapies  aiming  at  tumor  eradication.  In  response  to 
cellular stress p53 regulates molecules involved in both 
the  death 
(extrinsic)  and  mitochondria-
dependent  (intrinsic)  apoptotic  pathways  [115].  In 
response  to  multiple  chemotherapeutic  drugs  two  pro-
apoptotic members of the TNFR superfamily, Fas/Apo1 
and  Killer/DR5,  are  regulated  in  a  p53-dependent 
manner  [116,117].  In  addition  to  stimulating  Fas 
transcription,  activated  p53  may  enhance  levels  of  Fas 
at  the  cell  surface  promoting  trafficking  of  the  Fas 
receptor  from  the  Golgi  [118].  Another  membrane-
bound protein that was identified as a p53 target gene is 
(PERP), 
p53  apoptosis  effector 
although the precise mechanism by which its induction 
occurs  has  not  being  fully  elucidated  [119]  (Figure  6). 
Regarding  the  apoptotic  function  of  the 
intrinsic 
pathway,  p53  seems  to  play  a  pivotal  role  because  it 
modulates  both  pro-survival  and  pro-apoptotic  Bcl-2 
family  members.  Indeed,  a  key  subset  of  the  Bcl-2 
family  genes  are  p53  targets,  including  Bax,  Noxa, 
PUMA  and  Bid  [120-122]  (Figure  6).  PUMA  gene  is 
extremely  effective  in  inducing  apoptotic  cell  death 
within  few  hours  and,  more  importantly,  knockout 
experiments  in  human  colorectal  cancer  cells  showed 
that PUMA is required for p53-induced apoptosis [123]. 
Moreover,  p53  appears  to  promote  the  convergence  of 
the 
through  Bid 
regulation.  Indeed,  Bid  gene  has  been  found  to  be 
transcriptionally  induced  by  p53  in  response  to  γ-
chemo-
Interestingly, 
irradiation 
sensitivity  to  the  DNA-damaging  agents  doxorubicin 
and 5-fluorouracil appears to be critically dependent  on  

intrinsic  and  extrinsic  pathways 

related  PMP-22 

cellular 

[124]. 

www.impactaging.com 

            610                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
Figure  6.  p53‐mediated  apoptosis.  Role  of  p53  in  both  the  extrinsic  and
the intrinsic pathway and their convergence through t‐Bid. 

the presence of wtp53 and Bid. Therefore, the induction 
of  Bid  by  p53  helps  to  sensitize  the  cells  to  the  toxic 
effects  of  chemotherapeutic  drugs  [124].  While  the 
induction  of  some  p53  target  genes  appears  to  be 
sufficient  to  initiate  apoptosis,  another  class  of  p53 
target genes (i.e., Apaf-1, caspase-6, and Bid) does not 
efficiently  induce  apoptosis  per  se  but  rather  sensitizes 
cancer  cells  to  the  effects  of  chemotherapeutic  agents, 
improving the apoptotic outcome [124-127]. Moreover, 
p53  also  participates  in  apoptosis  induction  in  a 
transcription-independent  way  by  acting  directly  at 
mitochondria [128]; mechanistically, p53 interacts with 
anti-apoptotic  Bcl-xL  as  well  as  pro-apoptotic  Bcl-2 
family  proteins  resulting  in  releasing  of  the  pro-
apoptotic  effectors  Bax/Bak  that  elicit  cytochrome-c 
release and procaspase-3 activation [129]. 

Waking up the guardian: p53 as a druggable target 

Because  of  its  critical  antitumor  function,  p53  is 
frequently targeted for inactivation and suffers disabling 
mutations  or  deletions  in  about  50%  of  all  malignant 
tumors. The other half of human cancers express wild-
type  p53  protein  that,  however,  can  be  inactivated  by 
deregulation of regulatory proteins [130]. Stimulation of 
disabled p53 pathways has been suggested as a valuable 
anticancer  strategy  and,  interestingly,  activated  wtp53 
may target cancer cells though sparing the normal ones 
[131] which is an important concern in clinical studies. 
The p53 oncosuppressor protein is normally kept at low 
level because subject to negative regulation by MDM2-
dependent proteasome degradation [132]; in response to 
genotoxic  stress,  however,  p53  undergoes  post-
translational  modifications  that  allow  the  protein  to 
escape MDM2 control, accumulate,  and become  active  

in 

p53 

shifting 

rescuing 

inhibition 

[133].  The  mdm2  gene  is  amplified  in  a  significant 
proportion  of  human  tumor  types,  thereby  contributing 
to  tumor  development  by  efficiently  reducing  the 
availability  of  a  functional  p53  protein  [134].  The 
MDM2-negative  regulation  of  p53  protein  can  be 
neutralized  by  specific  protein  modifications  such  as 
serine  46  (Ser46)  phosphorylation  [135],  a  key 
the  p53  pro-apoptotic 
determinant 
transcription in response, for instance, to UV irradiation 
and  chemotherapy  [136,137].  In  particular,  p53-Ser46 
phosphorylation  by  kinase  HIPK2  is  able  to  neutralize 
p53 
MDM2-mediated 
transcriptional  activity  of  pro-apoptotic  factors  such  as 
p53AIP1, PIG3, Bax, Noxa, Puma and Killer/DR5 [138-
142].  The  interaction  between  p53  and  MDM2  is  a 
promising  target  in  anticancer  therapy  [143].  To  this 
aim, various peptidomimetic small molecules have been 
developed as protein-protein interaction blockers [144]. 
Among these is Nutlin-3, an imidazoline-based MDM2 
antagonist  that  potentially  inhibits  the  p53/MDM2 
interaction 
ligase 
activity  [145].  The  pharmacological  action  of  Nutlin-3 
is  through  both  the  transcription-dependent  and  -
independent  p53  apoptotic  pathways  [128,146,147]. 
MDM2  can  also  trigger,  in  response  to  low  genotoxic 
damage,  the  downregulation  of  p53  apoptotic  activator 
HIPK2  [148].  In  agreement,  the  use  of  Nutlin-3  has 
been shown to  mainly induce  mitotic arrest rather than 
apoptosis  [149].  Interestingly,  co-treatment  of  cancer 
cells  with  zinc  ion  in  the  presence  of  Nutlin-3  can 
interfere  with  the  interplay  between  HIPK2,  p53  and 
MDM2  favoring  HIPK2  stabilization  and  induction  of 
p53  apoptotic  activity  through  inhibition  of  MDM2 
ligase  activity  [150].  In  addition,  p53  apoptotic 
activation  can  be  achieved  by  zinc  combination  with 

though  maintaining  MDM2  E3 

www.impactaging.com 

            611                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in 

are 

such 

trials 

clinical 

effect;  mechanistically, 

low-dose  doxorubicin  (ADR)  that  used  alone  does  not 
achieve 
zinc 
supplementation  reduces  the  p53  binding  to  MDM2, 
improving  the  low-dose  drug-induced  cytotoxic  effect 
and  cancer  cell  apoptosis  [151].  Additionally,  zinc  ion 
restores  the  HIPK2/p53  apoptotic  pathway  that  is 
inhibited by hypoxia [152]. Co-treatment with Nutlin-3 
and Bcl-2 inhibitor ABT-737 has been shown to greatly 
enhance the sensitivity to apoptosis of cancer cells with 
high MDM2 levels [153], suggesting that the combined 
inhibition of MDM2 and Bcl-2 could be a multi-target-
based  anticancer  strategy  to  trigger  tumor  death  [154]. 
Some  p53  activators  as  small-molecules  MDM2 
antagonist 
[155] 
(https://clinicaltrials.gov).  In  contrast  with  the  majority 
of  the  approaches  that  target  the  interaction  between 
p53  and  MDM2,  a  new  method  has  been  developed 
aimed  at  inhibiting  the  activity  of  the  MDM2/MDM4 
complexes  by  interfering  with  their  heterodimerization 
[156]. The binding of the peptide mimicking the MDM4 
C-terminus tail to MDM2 impairs MDM2-mediated p53 
ubiquitination and activates p53-dependent transcription 
and  oncosuppressive  activities  [156].  MDM4  (also 
known as HDM4, MDMX or HDMX) is a cytoplasmic 
protein  with  p53-activating  function  under  DNA 
damage  conditions.  Particularly,  MDM4  promotes 
mitochondrial  localization  of  p53  phosphorylated  at 
cytoplasmic 
Ser46 
assembly,  uncovering  coordinated 
repression  of 
molecules  with  anti-apoptotic  activity  such  as  Bcl-2, 
release  of  cytochrome-c  and  apoptosis  [157,158].  The 
existence of nuclear and cytoplasmic complexes able to 
stimulate  the  same  p53  modification,  that  is  Ser46P, 
may  indicate  the  presence  of  overlapping  pathways  to 
ensure the proper realization of a crucial process as the 
the  potential 
apoptosis.  These 
therapeutic  value  of 
the  MDM2/MDM4 
heterodimers for p53 apoptotic function. 

findings  highlight 
targeting 

through  MDM4/HIPK2/p53 

field  of 

research  under 

Pharmacological reactivation of mutant (mut) p53 is an 
interesting 
continuous 
development  aimed  at  designing  new  drugs.  Some  of 
them exploit the intrinsically unstable nature of mutp53 
and  therefore  the  possibility  to  stabilize  the  wild-type 
conformation  thus  restoring  wild-type  function  and 
tumor  response  to  therapies.  Numerous  findings  about 
this  subject  have  been  shown  and  summarized  in 
different reviews [159-161]. 

MicroRNA and apoptosis 

MicroRNAs  (miRNAs)  are  highly  conserved,  small 
post-
noncoding 
transcriptionally regulate gene expression via inhibition 
of  mRNA  translation  or  inducing  degradation  of  target 

molecules, 

which 

RNA 

in 

involved 

consequent 

in  cancer, 

regulation.  Among 
regulating 

mRNAs  [162].  They  are  key  regulators  of  many  cell 
processes  often  deregulated 
including 
apoptosis.  Indeed,  it  is  becoming  clear  that  miRNAs 
might  act  as  both  anti-apoptotic  and  pro-apoptotic  by 
directly  targeting,  respectively,  pro-  or  anti-apoptotic 
mRNAs or their positive regulators [163]. The currently 
known apoptosis-regulating miRNAs list is expected to 
expand quickly and hopefully also their therapeutic use; 
just  highlight  here  some  miRNAs 
therefore,  we 
the 
involved 
apoptosis 
in 
the  extrinsic 
microRNAs 
apoptotic  pathway,  miR-20a,  miR-21,  miR-196b  and 
miR-590  were  reported  as  potential  modulator  of 
Fas/FasL  system  in  different  cancer  types  [164-167], 
while MiR-34a, miR-181c and miR-187 were shown to 
directly  target  TNF-α  mRNA  [168-170].  Among  the 
microRNAs involved in regulating the intrinsic pathway 
there are the let-7 family, miR-15a, miR-16-1, miR-204, 
and miR-608, just to mention a few. The Let-7 family is 
highly conserved in sequence across animal species and 
is  one  of  the  first  identified  miRNA  families.  Let-7 
miRNAs  have  been  shown  to  negatively  regulate  Bcl-
xL expression in human hepatocellular carcinomas and 
induce  apoptosis  in  cooperation  with  anti-cancer  drug 
targeting Mcl-1 [171]. Bcl-2 mRNA may be targeted by 
miR-204  with 
cells 
responsiveness  to  both  5-fluorouracil  and  oxaliplatin 
treatments  and  therefore  to  apoptotic  cell  death  [172]. 
MiR-608  has  been  reported 
in 
chordoma  malignancy  and  lung  cancer  [173].  Notably, 
numerous miRNAs are also transcriptionally modulated 
by wtp53 [174] and among them is miR-34a [175,176], 
a  member  of  the  MiR-34  family  implicated  in  cell 
death/survival signaling. MiR-34a is associated with G1 
cell  cycle  arrest,  senescence  and  apoptosis,  thereby 
possessing a tumor suppressor activity. Deregulation of 
MiR-34a  has  been  reported  in  several  types  of  cancers 
[175,176].  Mutant  (mut)  p53  was  also  found  to  play  a 
role  in  the  regulation  of  miRNA  processing.  Garibaldi 
and  collaborators  demonstrate  that  mutp53  proteins 
modulate  the  biogenesis  of  several  miRNAs  in  cancer 
cells  directly  interfering  with  Drosha-p72  association 
and  promoting  cell  survival  and  cell  migration  [177]. 
They  demonstrate  a  global  impact  of  mutp53  on 
miRNA  biogenesis  and  suggest  that  miRNAs  are 
downregulated  by  mutp53  in  order  to  inactivate  tumor 
suppressive  pathways.  Of  note  they  found  that  the 
endogenous  wtp53  has  an  opposite  effect  on  the 
expression  of  mutp53  repressed  miRNAs  on  colon 
cancer cell lines confirming the contribution of mutp53 
gain  of  oncogenic 
(GOF)  on  miRNA 
function 
repression  [177].  Additional  studies  on  a  large  scale 
would  help  in  identifying  the  entire  repertoire  of 
miRNAs negatively downregulated by different mutp53 
in different tumor models. According to the authors, the 

target  Bcl-xL 

increase 

in 

to 

www.impactaging.com 

            612                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
characterization  of  the  entire  gene-regulatory  networks 
governed  by  mutp53-miRNA  cross-talks  will  offer  a 
molecular basis for diagnostic and therapeutic strategies 
based  on  miRNA  biology. 
the  meanwhile, 
developing  strategies  to  block  mutp53  GOF  may  have 
clinical impact in cancer treatment. 

In 

benefit  of  patients,  although  the  mechanisms  defining 
their  mode  of  action  still  need  to  be  unveiled,  as 
[178].  Some  molecules  or 
recently  highlighted 
therapeutic  strategies  are  in  preclinical  trial,  others  are 
already  in  clinical  trials,  though  underscoring  the 
usefulness of such discoveries. 

of 

for 

the 

the 

study 

treatment 

investigate 

Delivery  of  miRNAs  as  synthetic  miRNA  mimics  or 
antagomirs  has  emerged  as  a  promising  approach  to 
treat  cancer.  Although  different  miRNAs  are  currently 
in  the  preclinical  stage  and  ready  to  enter  Phase  1 
clinical trials, to date, only two miRNA therapeutics are 
registered 
cancers 
[https://clinicaltrials.gov].  The  first  therapeutic  trial 
began in 2013 and is a Phase I, open-label, multicenter, 
dose-escalation 
safety, 
to 
pharmacokinetics and pharmacodynamics of MRX34 in 
patients  with  unresectable  primary  liver  cancer  or 
advanced/metastatic  cancer  with  or  without 
liver 
in  patients  with  hematologic 
involvement  or 
malignancies (Mirna Therapeutics). MRX34 is based on 
the  formulation  of  miR-34  mimic  and  the  liposomal 
delivery  technology  SMARTICLES  (Marina  Biotech). 
The  second  one,  began  in  early  2015,  and  is  an  early 
stage  clinical  trial  of  a  new  therapeutical  approach  for 
selected  patients  with  malignant  pleural  mesothelioma 
or  non-small  cell  lung  cancer.  The  trial  aims  to  test 
optimal dose of TargomiRs, an experimental medication 
consisting  of  three  components,  that  is,  miR-16-based 
microRNA  mimic, a nanoparticle drug delivery system 
using  nonliving  bacterial  minicells,  and  an  anti-
epidermal growth factor receptor antibody as a targeting 
moiety.  The  trial  is  being  carried  out  in  three  different 
hospitals  in  Australia  and  the  study  is  expected  to  be 
completed in mid 2016. 

for 

However, 
the  study  of  apoptosis  still  presents 
challenges  that  should  be  addressed  in  future  studies. 
They  include,  for  instance,  the  study  of  3-D  cellular 
models,  since  most  of  the  findings  have  been  so  far 
produced in 2-D cell culture systems. Knowing that the 
tumor  is  a  three-dimensional  entity  and  that  the 
environment  plays  a  big  role  in  the  cross-talk  with 
cancer cells, it is likely that more physiological studying 
the  apoptotic 
approach 
the  manipulation  of 
machinery  might  give  us  novel 
the 
into 
mechanisms  of  tumor  development  and  response  to 
therapies.  Moreover,  additional 
the 
development of drugs aiming at targeting, for instance, 
IAP  proteins  or  mutp53  should  take  in  consideration 
also  the  in  vivo  toxicity  and  the  fact  that  they  should 
selectively  induce  apoptosis  in  malignant  and  not  in 
normal  cells.  In  conclusion,  there  is  little  doubt  that 
drugs  that  target  the  deregulated  apoptotic  pathways 
could have wide application in the treatment of cancer. 
The intense effort devoted lately to target the apoptotic 
the 
is  encouraging  and  supportive 
pathway 
development  of  new  approaches  to  drug  discovery  and 
therapy. 

studies  on 

insight 

for 

Funding 

This  work  was  supported  by  AIRC  Grant  (IG  2015 
Id.16742) to GDO. 

Concluding remarks 

Conflict of interest statement 

Intensive  investigation  in  the  last  decades  on  the 
molecular  mechanisms  of  apoptosis  in  cancer  cells  has 
led  to  the  identification  of  the  several  molecules 
involved in both the intrinsic and the extrinsic apoptotic 
pathways.  This 
the  extensive 
is  underscored  by 
literature  that  those  studies  have  produced  in  the  last 
years.  Those  findings  also  reported  how  the  many 
different  alterations  of  key  players  of  the  apoptotic 
mechanisms  are  responsible  of  evasion  from  apoptosis 
and  therefore  of  tumor  development  and  resistance  to 
therapies. For that reason, evasion from apoptosis is an 
hallmark of cancer and apoptotic proteins are interesting 
therapeutic  targets.  Therefore,  this  insight  into  the 
deregulation  of  apoptosis  has  focused  the  research 
the  development  of  apoptosis-
attention 
reactivating  strategies,  to  be  used  in  the  treatment  of 
various types of cancer, that hold great promise for the 

towards 

The authors declare no conflict of interest. 

REFERENCES 

in  animal 

in  cancer:  from  pathogenesis  to 

1.  Fuchs  Y,  Steller  H.  Programmed  cell  death 
development and disease. Cell. 2011; 147; 742–758. 
2.  Wong  RSY.  Apoptosis 
treatment. JECCR. 2011; 30:87. 
3.  Plati  J,  Bucur  O,  Khosravi‐Far  R.  Dysregulation  of  apoptotic 
signaling  in  cancer.  Molecular  mechanisms  and  therapeutic 
opportunities. J Cell Biochem. 2008; 104:1124‐1149. 
4.  Fulda  S.  Tumor  resistance  to  apoptosis.  Int  J  Cancer.  2009; 
124:515‐515. 
5.  Hanahan  D,  Weinberg  RA.  Hallmarks  of  cancer:  The  next 
generation. Cell. 2011; 144:646‐674. 
6.  Gimenez‐Bonafe  P,  Tortosa  A,  Perez‐Tomas  R.  Overcoming 
drug  resistance  by  enhancing  apoptosis  of  tumor  cells.  Curr 
Cancer Drug Targ. 2009; 9:320‐340. 

www.impactaging.com 

            613                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.  Fulda  S.  Targeting  apoptosis  for  anticancer  therapy.  Sem 
Cancer Biol. 2015; 31:84‐88. 
8. Hacker G. The morphology of apoptosis. Cell Tissue Res. 2000; 
301:5‐17. 
9. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of 
apoptosis. Cardiovasc Res. 2000; 45:528‐537. 
10. Hengartner MO. Apoptosis: corralling the corpses. Cell. 2000; 
104:325‐328. 
11.  Kroemer  G,  El‐Deiry  WS,  Golstein  P,  Peter  ME,  Vaux  D, 
Vandenabeele  P,  Zhivotovsky  B,  Blagosklonny  MV,  Malorni  W, 
Knight RA, Piacentini M, Nagata S, Melino G. Classification of cell 
death:  recommendations  of  the  Nomenclature  Committee  on 
Cell Death. Cell Death Diff. 2005; 12:1463‐1467. 
12.  Bucur  O,  Nat  R,  Cretoiu  D,  Popescu  LM.  Phagocytosis  of 
apoptotic cells by microglia in vitro. J Cell Mol Med. 2001; 5:438‐
441. 
13.  Li  J,  Yuan  J.  Caspases  in  apoptosis  and  beyond.  Oncogene. 
2008; 27:6194‐6206. 
14.  Thomberry  NA,  Laxebnik  Y.  Caspases:  enemies  within. 
Science 1998; 281:1312‐1316. 
15. Nicholson DW. Caspase structure, proteolytic substrates, and 
function  during  apoptotic  cell  death.  Cell  Death  Diff.  1999; 
6:1028‐1042. 
16.  Stennicke  HR,  Salvesen  GS.  Caspases 
‐ controlling  
intracellular  signals  by  protease  zymogen  activation‐  Biochim 
Biophys Acta‐Port Struct Mol Enzimol. 2000; 1477:299‐306. 
17.  Degterev  A,  Boyce  M,  Yuan  JY.  A  decade  of  caspases. 
Oncogene. 2003; 22:8543‐8567. 
18. Pistritto G, Jost M, Srinivasula SM, Baffa R, Poyet JL, Kari C, 
Lazebnik Y, Rodeck U, Alnemri ES. Expression and transcriptional 
regulation  of  caspase‐14  in  simple  and  complex  epithelia.  Cell 
Death Diff. 2002; 9:995‐1006. 
19.  Pistritto  G,  Papaleo  V,  Sanchez  P,  Ceci  C,  Barbaccia  ML. 
Divergent  modulation  of  neuronal  differentiation  by  caspase‐2 
and‐9. PLoS ONE. 2012; 7:e36002. 
20.  Shalini  S,  Dorstyn  L,  Dawar  S  and  Kumar  S.  Old,  new  and 
emerging  functions  of  caspases.  Cell  Death  Diff.  2015;  22:  526‐
39. 
21.  Guicciardi  ME,  Gores,  Gregory  J.  Life  and  death  by  death 
receptors FASEB J. 2009; 23:1625‐1637. 
22.  Fulda  S,  Debatin  KM.  Death  receptor  signaling  in  cancer 
therapy. Curr Med Chem Anticancer Agents. 2003; 3: 253‐262. 
23.  Boatright  KM,  Salvesen  GS.  Mechanisms  of  caspase 
activation. Curr Opin Cell Biol. 2003; 6:725‐731. 
24. Green DR, Kroemer G. The pathophysiology of mitochondrial 
cell death. Science 2004; 305:626‐629. 
25.  Kroemer  G, Galluzzi  L,  Brenner  C:  Mitochondrial  membrane 
permeabilisation in cell death. Physiol Rev. 2007; 87:99‐163. 
26.  Danial  NN,  Korsmeyer  SJ.  Cell  death:  critical  control  points. 
Cell. 2004; 116:205‐219. 
27.  Slee  EA,  Adrain  C,  Martin  SJ.  Serial  killers:  ordering  caspase 
activation  events  in  apoptosis.  Cell  Death  Diff.  1999;  6:1067‐
1074. 
28.  Kuribayashi  K,  Mayes  PA,  El‐Dery  WS.  What  are  caspases  3 
and  7  doing  upstream  of  the  mitochondria?  Cancer  Biol  Ther. 
2006; 5:763‐765. 
29.  Giam  M,  Huang  DC,  Bouillet  P.  BH3‐only  proteins  and  their 
roles in programmed cell death. Oncogene. 2008; 27:S128‐36. 
30.  Adams  JM,  Cory  S.  The  Bcl‐2  apoptotic  switch  in  cancer 
development and therapy. Oncogene. 2007; 26:1324‐1337. 

31.  Danial  NN.  BCL‐2  family  proteins:  Critical  checkpoints  of 
apoptotic cell death. Clin Cancer Res. 2007; 13:7254‐7263. 
32.  Lomonosova  E  and  G  Chinnadurai.  BH3‐only  proteins  in 
apoptosis  and  beyond:  an  overview.  Oncogene.  2009;  27:S2–
S19. 
33.  Youle  RJ,  Strasser  A.  The  BCL‐2  protein  family:  opposing 
activities that mediate cell death. Nat Rev Mol Cell Biol. 2008; 9: 
47‐59. 
34.  Dewson  G,  Kratina  T,  Sim  HW,  Puthalakath  H,  Adams  JM, 
Colman PM, Kluck RM. To trigger apoptosis, Bak exposes its BH3 
domain  and  homodimerizes  via  BH3  :  Groove  interactions.  Mol 
Cell. 2008; 30:369‐380. 
35. Bleicken St, Classen M, Padmavathi PVL, Ishikawa T, Zeth K, 
Steinhoff  HJ,  Bordignon  E.  Molecular  details  of  Bax  activation, 
oligomerization,  and  membrane  insertion.  J  Biol  Chem.  2010; 
285: 6636‐6647. 
36. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, 
Tu HC, Kim H, Cheng EH, Tjandra N, Walensky LD. BAX activation 
is initiated at a novel interaction site. Nature. 2008; 455:1076‐U6  
37.  Brunelle  JK,  Letai  A.  Control  of  mitochondrial  apoptosis  by 
the Bcl‐2 family. J Cell Sci. 2009; 122:437‐441. 
38.  Oakes  SA,  Scorrano  L,  Opferman  JT,  Bassik  MC,  Nishino  M, 
Pozzan T, Korsmeyer SJ. Proapoptotic BAX and BAK regulate the 
type 1 inositol trisphosphate receptor and calcium leak from the 
endoplasmic  reticulum.  Proc  Natl  Acad  Sci  USA.  2005;  102:105‐
110. 
39.  Distelhorst  CW,  Bootman  MD.  Bcl‐2  interaction  with  the 
inositol 1,4,5‐trisphosphate receptor: Role in Ca2+ signaling and 
disease. Cell Calcium. 2011; 50:234‐241. 
40.  Hegde  R,  Srinivasula  SM,  Zhang  Z,  Wassell  R,  Mukattash  R, 
Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes‐Alnemri T, 
Alnemri  ES.  Identification  of  Omi/HtrA2  as  a  mitochondrial 
apoptotic  serine  protease  that  disrupts  inhibitor  of  apoptosis 
protein‐caspase interaction.  J Biol Chem. 2002; 277: 432‐438. 
41. Pop C, Salvesen GS. Human caspases: activation, specificity, 
and regulation. J Biol Chem. 2009; 284:21777‐21781. 
42. Salvesen GS and Duckett CS. IAP proteins: Blocking the road 
to death’s door. Nat Rev Mol Cell Biol. 2002; 3:401:410. 
43. Berthelet J, Dubrez L. Regulation of apoptosis by inhibitors of 
apoptosis (IAPs). Cells. 2013; 2:163‐87. 
44. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, 
Korneluk  RG:  IAP‐targeted  therapies  for  cancer.  Oncogene. 
2008; 27:6252‐6275. 
45. Mace PD, Shirley S, Day CL. Assembling the building blocks: 
structure  and  function  of  inhibitor  of  apoptosis  proteins.  Cell 
Death Differ. 2010; 17:46‐53. 
46.  Müschen  M,  Beckmann  MW.  CD95  ligand  expression  as  a 
criterion  of  malignant  transformation  in  breast  cancer  J  Pathol. 
2000; 191: 468‐470. 
47.  Tourneur  L,  Buzyn  A,  Chiocchia  G.  FADD  adaptor  in  cancer. 
Med Immunol. 2005; 4:1. 
48. Müschen M, Rajewsky K, Krönke M, Küppers R. The origin of 
CD95‐gene  mutations  in  B‐cell  lymphoma.  Trends  Immunol. 
2002; 23:75‐80. 
49.  Tourneur  L,  Delluc  S,  Levy  V,  Valesi  F,  Radford‐Weiss  I, 
Legrand O, Vargftig J, Boix C, Macintyre EA, Varet B, Chiocchia G, 
Buzyn  A.  Absence  or  low  expression  of  fas‐associated  protein 
with  death  domain  in  acute  myeloid  leukemia  cells  predicts 
resistance  to  chemotherapy  and  poor  outcome.  Cancer  Res. 
2004; 64: 8101‐8108. 

www.impactaging.com 

            614                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
primitive 

neuroectodermal 

50.  Teitz  T,  Wei  T,  Valentine  MB,  Vanin  EF,  Grenet  J,  Valentine 
VA, Behm FG, Look AT, Lahti JM, Kidd VJ. Caspase 8 is deleted or 
in  childhood  neuroblastomas  with 
silenced  preferentially 
amplification of MYCN. Nat Med. 2000; 6: 529‐535. 
51.  Shivapurkar  N,  Toyooka  S,  Eby  MT,  Huang  CX, 
Sathyanarayana  UG,  Cunningham  HT,  Reddy  JL,  Brambilla  E, 
Takahashi  T,  Minna  JD,  Chaudhary  PM,  Gazdar  AF.  Differential 
inactivation of caspase‐8 in lung cancers. Cancer Biol Ther. 2002; 
1: 65‐69. 
52.  Zuzak  TJ,  Steinhoff  DF,  Sutton  LN,  Phillips  PC,  Eggert  A, 
Grotzer  MA.  Loss  of  caspase‐8  mRNA  expression  is  common  in 
brain 
childhood 
tumor/medulloblastoma. Eur J Cancer. 2002; 38: 83‐91. 
53.  Irmler  M,  Thome  M,  Hahne  M,  Schneider  P,  Hofmann  K, 
Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi 
D,  French  LE,  Tschopp  J.  Inhibition  of  death  receptor  signals  by 
cellular FLIP. Nature. 1997; 388: 190‐195. 
54.  Bagnoli  M,  Canevari  S,  Mezzanzanica  D.  Cellular  FLICE‐
inhibitory protein (c‐FLIP) signalling: A key regulator of receptor‐
mediated  apoptosis  in  physiologic  context  and  in  cancer.  Int  J 
Biochem Cell Biol. 2010; 42:210–213. 
55. Shirley S, Micheau O. Targeting c‐FLIP in cancer. Cancer Lett. 
2013; 332:141‐150. 
56. Gandour‐Edwards R, Mack PC, Devere‐White RW, Gumerlock 
PH. Abnormalities of apoptotic and cell cycle regulatory proteins 
in  distinct  histopathologic  components  of  benign  prostatic 
hyperplasia. Prost Cancer Prost Dis. 2004; 7:321‐326. 
57. Abramson JS, Shipp MA. Advances in the biology and therapy 
of  diffuse  large  B‐cell  lymphoma:  moving  toward  a  molecularly 
targeted approach. Blood. 2005; 106:1164‐1174. 
58.  Watanabe  A,  Yasuhira  S,  Inoue  T,  Kasai  S,  Shibazaki  M, 
Takahashi K, Akasaka T, Masuda T, Maesawa C. BCL2 and BCLxL 
are 
antitubulin 
chemotherapeutics  in  melanoma  cells.  Exp  Dermatol.  2013;  22: 
518‐523. 
59.  Raffo  AJ,  Perlman  H,  Chen  MW,  Day  ML,  Streitman  JS, 
Buttyan R. Overexpression of bcl‐2 protects prostate cancer cells 
from  apoptosis  in  vitro  and  confers  resistance  to  androgen 
depletion in vivo. Cancer Res. 1995; 55:4438. 
60.  Fulda  S,  Meyer  E,  Debatin  KM.  Inhibition  of  TRAIL‐induced 
apoptosis  by  Bcl‐2  overexpression.  Oncogene.  2000;  21:2283‐
2294. 
61.  Foreman  KE,  Wrone‐Smith  T,  Boise  LH,  Thompson  CB, 
Polverini  PJ,  Simonian  PL,  Nunez  G,  Nickoloff  BJ.  Kaposi’s 
sarcoma  tumor  cells  preferentially  express  Bcl‐xL  Am  J  Pathol. 
1996; 149: 795‐803. 
62. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. 
Elevated  expression  of  Bcl‐X  and  reduced  Bak  in  primary 
colorectal adenocarcinomas. Cancer Res. 1996; 56: 2422‐2427. 
63.  Minn  AJ,  Rudin  CM,  Boise  LH,  Thompson  CB.  Expression  of 
Bcl‐xL can confer a multidrug resistance phenotype. Blood. 1995; 
86:1903‐1910. 
64. Han JY, Hong EK, Choi BG, Park JN, Kim KW, Kang JH, Jin JY, 
Park  SY,  Hong  YS,  Lee  KS  Death  receptor  5  and  Bcl‐2  protein 
expression as predictors of tumor response to gemcitabine and 
cisplatin  in  patients  with  advanced  non‐small‐cell  lung  cancers. 
Med Oncol. 2003; 20:355‐362. 
65.  Erovic  BM,  Pelzmann  M,  Grasl  MCh,  Pammer  J,  Kornek  G, 
Brannath  W,  Selzer  E,  Thurnher  D.  Mcl‐1,  vascular  endothelial 
growth  factor‐R2,  and  14‐3‐3sigma  expression  might  predict 
primary  response  against  radiotherapy  and  chemotherapy  in 

determinants 

resistance 

key 

to 

of 

leukaemia  and  their  correlation  with 

patients with locally advanced squamous cell carcinomas of the 
head and neck. Clin Cancer Res. 2005; 11:8632‐8636. 
66.  Williams  J,  Lucas  PC,  Griffith  KA,  Choi  M,  Fogoros  S,  Hu  YY, 
Liu  JR.  Expression  of  Bcl‐xL  in  ovarian  carcinoma  is  associated 
with  chemoresistance  and  recurrent  disease.  Gynecol  Oncol. 
2005; 96: 287‐295. 
67.  Michaud  WA,  Nichols  AC,  Mroz  EA,  Faquin  WC,  Clark  JR, 
Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW. 
Bcl‐2  blocks  cisplatin‐induced  apoptosis  and  predicts  poor 
outcome  following  chemoradiation  treatment 
in  advanced 
oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009; 
15: 1645‐1654. 
68.  Yang  D,  Chen  MB,  Wang  LQ,  Yang  L,  Liu  CY,  Lu  PH.  Bcl‐2 
expression predicts sensitivity to chemotherapy in breast cancer: 
a systematic review and meta‐analysis. JECCR 2013; 32:105. 
69.  Miquel  C,  Borrini  F,  Grandjouan  S,  Aupérin  A,  Viguier  J, 
Velasco V, Duvillard P, Praz F, Sabourin JC. Role of bax mutations 
in  apoptosis  in  colorectal  cancers  with  microsatellite  instability. 
Am J Clin Pathol. 2005; 23:562‐570. 
70.  Pepper  C,  Hoy  T,  Bentley  DP.  Bcl‐2/Bax  ratios  in  chronic 
lymphocytic 
in  vitro 
apoptosis and clinical resistance. Br J Cancer. 1997; 76:935‐938. 
71. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz‐
Araya  X,  McCombie  R,  Herman  JG,  Gerald  WL,  Lazebnik  YA, 
Cordón‐Cardó C, Lowe SW. Inactivation of the apoptosis effector 
Apaf‐1 in malignant melanoma. Nature. 2001; 409:207‐211. 
72. Baldi A, Santini D, Russo P, Catricala’ C, Amantea A, Picardo M, 
Tatangelo F, Botti G, Dragonetti E, Murace R, Tonini G, Natali PG, 
Baldi  F,  Paggi  MG.  Analysis  of  APAF‐1  expression  in  human 
cutaneous melanoma progression. Exp Dermatol. 2004; 13:93‐97. 
73.  Schimmer  AD.  Inhibitor  of  apoptosis  proteins:  translating 
basic  knowledge  into  clinical  practice.  Cancer  Res.  2004;  64: 
7183‐7190. 
74.  Fulda  S.  Inhibitor  of  apoptosis  proteins  in  hematological 
malignancies. Leukemia. 2009; 23:467‐476. 
75.  Fulda  S,  Debatin  KM.  IFNgamma  sensitizes  for  apoptosis  by 
upregulating  caspase‐8  expression  through  the  Stat1  pathway. 
Oncogene. 2002; 21:2295‐2308. 
76.  Subramanian  K,  Hirpara  JL,  Tucker‐Kellogg  L,  Tucker‐Kellogg 
G, Pervaiz S. FLIP: A flop for execution signals. Cancer Lett. 2013; 
332:151‐155. 
77.  Almasan  A,  Ashkenazi  A.  Apo2L/TRAIL:  apoptosis  signaling, 
biology,  and  potential  for  cancer  therapy.  Cytok  Growth  Fact 
Rev. 2003; 14:337‐348. 
78.  Amarante‐Mendes  GP,  Griffith  TS.  Therapeutic  applications 
of  TRAIL  receptor  agonists  in  cancer  and  beyond.  Pharmacol 
Ther. 2015; 155:117‐131. 
79. Bucur O, Gaidos G, Yatawara A, Pennarum B, Rupasinghe C, 
Roux  J,  Andrei  S,  Guo  B,  Panaititu  A,  Pellegrini  M,  Mierke  DF, 
Khosravi‐Far  R.  A  novel  caspase  8  selective  small  molecule 
potentiates TRAIL‐induced cell death. Sci Rep. 2015; 5:9893. 
80. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters 
SA,  Blackie  C,  Chang  L,  McMurtrey  AE,  Hebert  A,  DeForge  L, 
Koumenis  IL,  Lewis  D,  et  al.  Safety  and  antitumor  activity  of 
recombinant  soluble  Apo2  ligand.  J  Clin  Invest.  1999;  104:155‐
162. 
81. LeBlanc H, Ashkenazi A. Apo2/TRAIL and its death and decoy 
receptors. Cell Death Diff. 2003; 10:66‐75. 
82.  Kang  MH,  Reynolds  CP.  Bcl‐2 
targeting 
mitochondrial apoptotic pathways in cancer therapy. Clin Cancer 
Res. 2009; 15:1126‐1132. 

inhibitors: 

www.impactaging.com 

            615                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
83.  Sonpavde  G,  Matveev  V,  Burke  JM,  Caton  JR,  Fleming  MT, 
Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood 
BA, Brookes M, Leopold L. Randomized phase II trial of docetaxel 
plus prednisone in combination with placebo or AT‐101, an oral 
small  molecule  Bcl‐2  family  antagonist,  as  first‐line  therapy  for 
metastatic  castration‐resistant  prostate  cancer.  Annal  Oncol. 
2012; 23:1803‐1808. 
84.  Stein  MN,  Hussain  M,  Stadler  WM,  Liu  G,  Tereshchenko  IV, 
Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, Di Paola RS. A 
Phase II study of AT‐101 to overcome Bcl‐2‐mediated resistance 
to  androgen  deprivation  therapy 
in  patients  with  newly 
diagnosed  castration‐sensitive  metastatic  prostate  cancer.  Clin 
Genitour Cancer. 2016; 14:22‐27. 
85.  Souers  AJ,  Leverson  JD,  Boghaert  ER,  Ackler  SL,  Catron  ND, 
Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang 
DCS,  Hymowitz  SG,  Jin  S,  et  al. ABT‐199,  a  potent  and selective 
inhibitor,  achieves  antitumor  activity  while  sparing 
BCL‐2 
platelets. Nat Med. 2013; 19:202‐208. 
86.  Oltersdorf  T,  Elmore  SW,  Shoemaker  AR,  Armstrong  RC, 
Augeri  DJ,  Belli  BA,  Bruncko  M,  Deckwerth  TL,  Dinges  J,  Hajduk 
PJ, Joseph MK, Kitada S, Korsmeyer SJ, et al. An inhibitor of Bcl‐2 
family proteins induces regression of solid tumors. Nature. 2005; 
435:677‐681. 
87. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, 
Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, 
Mao  Y,  Yang  X,  Zhang  HC,  Fesik  S,  Rosenberg  SH,  Elmore  SW. 
ABT‐263: a potent and orally bioavailable Bcl‐2 family inhibitor. 
Cancer Res. 2008; 68:3421‐3428. 
88.  Roberts  AW,  Seymour  JF,  Brown  JR,  Wierda  WG,  Kipps  TJ, 
Khaw SL, Carney DA, He SZ, Huang DCS, Xiong H, Cui Y, Busman 
TA,  McKeegan  EM,  et  al.  Substantial  susceptibility  of  chronic 
lymphocytic  leukemia  to  BCL2  inhibition:  results  of  a  phase  I 
study  of  navitoclax  in  patients  with  relapsed  or  refractory 
disease. J Clin Oncol. 2012; 30:488‐496. 
89.  Chiappori  A,  Williams  C,  Northfelt  DW,  Adams  JW,  Malik  S, 
Edelman  MJ,  Rosen  P,  Van  Echo  DA,  Berger  MS,  Haura  EB. 
Obatoclax  mesylate,  a  pan‐bcl‐2  inhibitor,  in  combination  with 
docetaxel  in  a  phase  1/2  trial  in  relapsed  non‐small‐cell  lung 
cancer. J Thorac Oncol. 2014; 9:121‐125. 
90.  Theile  D,  Allendorf  D,  Koehler  BC,  Jassowicz  A,  Weiss  J. 
Obatoclax  as  a  perpetrator  in  drug‐drug  interactions  and  its 
efficacy  in  multidrug  resistance  cell  lines.  J  Pharm  Pharmacol. 
2015; 67:1575‐1584. 
91.  Zeitlin  BD,  Joo  E,  Dong  Z,  Warner  K,  Wang  G,  Nikolovska‐
Coleska  Z,  Wang  S,  Nor  JE.  Antiangiogenic  effect  of  TW37,  a 
small‐molecule  inhibitor  of  Bcl‐2.  Cancer  Res.  2006;  66:8698‐
8706. 
92. Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, et 
al.  Discovery  of  a  potent  and  selective  Bcl‐xL  inhibitor  with  in 
vivo activity. ACS Med Chem Lett. 2014; 5:1088‐1093. 
93. Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, 
et al. Structure‐guided design of a series of MCL‐1 inhibitors with 
high affinity and selectivity. J Med Chem. 2015; 58:2180–2194. 
94. Vervloessem T, La Rovere R, Bultynck G. Antagonizing Bcl‐2's 
BH4 domain in cancer. Aging (Albany NY). 2015; 7:748‐749. doi: 
10.18632/aging.100828. 
95. Trisciuoglio D, Gabellini C, Desideri M, Ragazzoni Y, De Luca 
T, Ziparo E, Del Bufalo D. Involvement of BH4 domain of bcl‐2 in 
the  regulation  of  HIF‐1‐mediated  VEGF  expression  in  hypoxic 
tumor cells. Cell Death Diff. 2011; 18:1024‐1035. 

96. Trisciuoglio D, De Luca T, Desideri M, Passeri D, Gabellini C, 
Scarpino S, Liang C, Orlandi A, Del Bufalo D. Removal of the BH4 
domain  from  Bcl‐2  protein  triggers  an  autophagic  process  that 
impairs tumor growth. Neoplasia. 2013; 15:315‐327. 
97. Gabellini C, De Luca T, Trisciuoglio D, Desideri M, Di Martile 
M,  Passeri  D,  Candiloro  A,  Biffoni  M,  Rizzo  MG,  Orlandi  A,  Del 
Bufalo  D.  BH4  domain  of  bcl‐2  protein  is  required  for  its 
proangiogenic function under hypoxic condition. Carcinogenesis. 
2013; 34:2558‐2567. 
98.  Han  B,  Park  D,  Li  R,  Xie  M,  Owonikoko  T,  Zhang  G,  Sica  GL, 
Ding  C,  Zhou  J,  Magis  AT,  Chen  ZG,  Shin  DM,  Ramalingam  S, 
Khuri  FR,  Curran  WJ,  Deng  X.  Small‐molecule  Bcl‐2  BH4 
antagonist  for  lung  cancer  therapy.  Cancer  Cell.  2015;  27:852‐
863. 
99.  Dexheimer  TS,  Sun  D,  Hurley  LH.  Deconvoluting  the 
structural and drug‐recognition complexity of the G‐quadruplex‐
forming  region  upstream  of  the  bcl‐2  P1  promoter.  J  Am  Chem 
Soc. 2006; 128:5404‐5415. 
100. Lin J, Hou JQ, Xiang HD, Yan YY, Gu YC, Tan JH, Li D, Gu LQ, 
Ou  TM,  Huang  ZS.  Stabilization  of  G‐quadruplex  DNA  by  C‐5‐
methyl‐cytosine  in  bcl‐2  promoter:implications  for  epigenetic 
regulation. Biochem Biophys Res Commun. 2013; 433:368‐373. 
101. Sun H, Xiang J, Shi Y, Yang Q, Guan A, Li Q, Yu L, Shang Q, 
Zhang  H,  Tang  Y,Xu  G.  A  newly  identified  G‐quadruplex  as  a 
potential  target  regulating  Bcl‐2  expression.  Biochim  Biophys 
Acta. 2014; 1840:3052‐3057. 
102.  Le  Pen  J,  Laurent  M,  Sarosiek  K,  Vuillier  C,  Gautier  F, 
Montessuit S, Martinou JC, Letaï A, Braun F, Juin PP. Constitutive 
p53  heightens  mitochondrial  apoptotic  priming  and  favors  cell 
death induction by BH3 mimetic inhibitors of BCL‐xL. Cell Death 
Dis. 2016; 7:e2083. 
103. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down‐regulation of 
X‐linked  inhibitor  of  apoptosis  protein  induces  apoptosis  in 
chemoresistant  human  ovarian  cancer  cells.  Cancer  Res.  2000; 
60: 5659‐5666. 
104.  Holcik  M,  Yeh  C,  Korneluk  RG,  Chow  T.  Translational 
upregulation  of  X‐linked  inhibitor  of  apoptosis  (XIAP)  increases 
resistance to radiation induced cell death. Oncogene. 2000; 19: 
4174‐4177. 
105.  Amantana  A,  London  CA,  Iversen  PL,  Devi  GR.  X‐linked 
inhibitor  of  apoptosis  protein  inhibition  induces  apoptosis  and 
enhances  chemotherapy  sensitivity  in  human  prostate  cancer 
cells. Mol Cancer Ther. 2004; 3:699‐707. 
106.  Fulda  S.  Promises  and  challenges  of  Smac  mimetics  as 
cancer therapeutics. Clin Cancer Res. 2015; 21:5030‐5036. 
107. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, 
Cockerill  M,  Cartlidge  S,  Smith  PD.  AZD6244  (ARRY‐142886),  a 
potent 
protein 
kinase/extracellular  signal‐regulated  kinase  kinase  1/2  kinases: 
mechanism of action in vivo, pharmacokinetic/pharmacodynamic 
relationship, and potential for combination in preclinical models. 
Mol Cancer Ther. 2007; 6:2209‐2219. 
108. Folkes AJ,  Ahmadi K, Alderton WK, Alix S,  Baker SJ, Box G, 
Chuckowree  IS,  Clarke  PA,  Depledge  P,  Eccles  SA,  Friedman  LS, 
Hayes A, Hancox TC, et al. The identification of 2‐(1H‐indazol‐4‐
yl)‐6‐(4‐methanesulfonyl‐piperazin‐1‐ylmethyl)‐4‐morpholin‐4‐
yl‐thieno[3,2‐d]  pyrimidine  (GDC‐0941)  as  a  potent,  selective, 
inhibitor  of  class  I  PI3  kinase  for  the 
orally  bioavailable 
treatment of cancer. J Med Chem. 2008; 51:5522–5532. 
109.  Hata  AN,  Yeo  A,  Faber  AC,  Lifshits  E,  Chen  Z,  Cheng  KA, 
Walton  Z,  Sarosiek  KA,  Letai  A,  Heist  RS,  Mino‐Kenudson  M, 

activated 

inhibitor 

mitogen 

of 

www.impactaging.com 

            616                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
lethal 
inhibition  promotes 

Wong  KK,  Engelman  JA.  Failure  to  induce  apoptosis  via  BCL‐2 
family  proteins  underlies  lack  of  efficacy  of  combined  MEK  and 
PI3K inhibitors for KRAS‐mutant lung cancers. Cancer Res. 2014; 
74:3146‐3156. 
110. Okamoto K, Zaanan A, Kawakami H, Huang S, Sinicrope FA. 
Reversal  of  mutant  KRAS‐mediated  apoptosis  resistance  by 
concurrent  Noxa/Bik  induction  and  Bcl‐2/Bcl‐xL  antagonism  in 
colon cancer cells. Mol Cancer Res. 2015; 13:659‐669. 
111.  Corcoran  RB,  Cheng  KA,  Hata  AN,  Faber  AC,  Ebi  H,  Coffee 
EM,  Greninger  P,  Brown  RD,  Godfrey  JT,  Cohoon  TJ,  Song  Y, 
interaction  of 
Lifshits  E,  Hung  KE,  et  al.  Synthetic 
tumor 
combined  BCL‐XL  and  MEK 
regressions  in  KRAS  mutant  cancer  models.  Cancer  Cell.  2013; 
23:121‐128. 
112.  Vousden  KH,  Lane  DP.  P53  in  health  and  disease.  Nat  Rev 
Mol Cell Biol. 2007;8:275–283. 
113.  Brooks  CL,  Gu  W.  Ubiquitination,  phosphorylation  and 
acetylation:  the  molecular  basis  for  p53  regulation.  Curr  Opin 
Cell Biol. 2003; 15:164‐171. 
114.  Haupt  S,  Berger  M,  Goldberg  Z,  Haupt  Y.  Apoptosis  –  the 
p53 network. J Cell Sci. 2003; 116:4077‐4085. 
115. Vousden KH. P53: Death Star. Cell. 2000; 103:691‐694. 
116. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz 
ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, 
Matkowitz  S,  et  al.  KILLER/DR5  is  a  DNA  damage‐induced  p53‐
regulated death receptor gene. Nat Genet. 1997; 17:141‐143. 
117.  Muller  M,  Wilder  S,  Bannasch  D,  Israeli  D,  Lehlbach  K,  Li‐
Weber  M,  Friedman  SL,  Galle  PR,  Stremmel  W,  Oren  M, 
Krammer  PH.  P53  activates  the  CD95  (APO‐1/Fas)  gene  in 
response to DNA damage by anticancer drugs. J Exp Med. 1998; 
188:2033‐2045. 
118.  Bennet  M,  Macdonald  K,  Chan  SW,  Luzio  JP,  Simari  R, 
Weissberg. Cell surface trafficking of Fas: a rapid mechanisms of 
p53‐mediated apoptosis. Science. 1998; 282:290‐293. 
119.  Attardi  LD,  Reczek  EE,  Cosmas  C,  Demicco  EG,  McCurrach 
ME,  Lowe  SW,  Jacks  T.  PERP,  an  apoptosi‐associated  target  of 
p53, is a novel member of the PMP‐22/gas3 family. Genes Dev. 
2000; 14:704‐718. 
120. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita 
T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3‐only member of 
the  Bcl‐2  family  and  candidate  mediator  of  p53‐induced 
apoptosis. Science. 2000; 288:1053‐1058. 
121. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, 
is induced by p53. Mol Cell. 2001; 7:683‐694. 
122.  Thornborrow  EC,  Patel  S,  Mastropietro  AE,  Schwartzfarb 
EM,  Manfredi  JJ.  A  conserved 
intronic  response  element 
mediates  direct  p53‐dependent  transcriptional  activation  of 
both the human and murine bax gene. Oncogene. 2002; 21:990‐
999. 
123.  Yu  J,  Wang  Z,  Kinzler  KW,  Vogelstein  B,  Zhang  L.  PUMA 
mediates  the  apoptotic  response  to  p53  in  colorectal  cancer 
cells. Proc Natl Acad Sci U S A. 2003; 100:1931‐1936. 
124.  Sax  JK,  Fei  P,  Murphy  ME,  Bernhard  E,  Korsmeyer  SJ,  El‐
Deiry WS. BID regulation by p53 contributes to chemosensitivity. 
Nat Cell Biol. 2002; 4: 842‐849. 
125.  Moroni  MC,  Hickman  ES,  Denchi  EL,  Caprara  G,  Colli  E, 
Cecconi F, Muller H, Helin K. Apaf‐1 is a transcriptional target for 
E2F and p53. Nat Cell Biol. 2001; 3:553‐558. 
126.  MacLachlan  TK,  and  El‐Deiry  WS.  Apoptotic  threshold  is 
lowered by p53 transactivation of caspase‐6. Proc Natl Acad Sci. 
2002; 99: 9492‐9497. 

insights 

127.  Sax  JK,  El‐Deiry  WS.  P53  downstream  targets  and 
chemosensitivity. Cell Death Diff. 2003; 10:413‐417. 
into  the  transcription‐
128.  Chi  SW.  Structural 
independent apoptotic pathway of p53. BMB Rep. 2014; 47:167‐
172. 
129. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, 
Klein C, Pan H, Kessler H, Pancoska P, Moll UM. WT p53, but not 
tumor‐derived  mutants,  bind  to  Bcl2  via  the  DNA  binding 
domain  and  induce  mitochondrial  permeabilization.  JBC  2006; 
281:8600–8606. 
130. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening 
guardian  angels:  drugging  the  p53  pathway.  Nat  Rev  Cancer. 
2009; 9:862–873. 
131.  D'Orazi  G,  Marchetti  A,  Crescenzi  M,  Coen  S,  Sacchi  A, 
Soddu S: Exogenous wt‐p53 protein is active in transformed cells 
but  not  in  their  nontransformed  counterparts:  implications  for 
cancer  gene  therapy  without  tumor  targeting.  J  Gene  Med. 
2000; 2: 11–21. 
132. Momand J, Wu HH, Dasgupta G. MDM2 ‐ master regulator 
of the p53 tumor suppressor protein. Gene. 2000; 242:15‐29. 
133.  Harris  SL,  Levine,  AJ.  The  p53  pathway:  positive  and 
negative feedback loops. Oncogene. 2005; 24:2899‐2908. 
134. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene 
amplification database. Nucleic Acids Res. 1998; 26:3453‐3459. 
135.  Di  Stefano  V,  Blandino  G,  Sacchi  A,  Soddu  S,  D’Orazi  G. 
HIPK2 neutralizes MDM2  inhibition rescuing p53 transcriptional 
activity and apoptotic function. Oncogene. 2004; 23:5185‐5192. 
136. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori 
T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AlP1, 
a  potential  mediator  of  p53‐dependent  apoptosis,  and  its 
regulation  by  Ser‐46‐phosphorylated  p53.  Cell.  2000;  102:849‐
862. 
137.  Mayo  LD,  Seo  YR,  Jackson  MW,  Smith  ML,  Guzman  JR, 
Korgaonkar  CK,  Donner  DB.  Phosphorylation  of  human  p53  at 
serine 46 determines promoter selection and whether apoptosis 
is attenuated or amplified. J Biol Chem 2005; 280:25953‐25959. 
138.  D’Orazi  G,  Cecchinelli  B,  Bruno  T,  Manni  I,  Higashimoto  Y, 
Saito  S,  Gostissa  M,  Coen  S,  Marchetti  A,  Del  Sal  G,  Piaggio  G, 
Fanciulli  M,  Appella  E,  et  al.  Homeodomain‐interacting  protein 
kinase  2  phosphorylates  p53  at  Ser46  and  mediates  apoptosis. 
Nat Cell Biol. 2002; 4:11‐19. 
139.  Di  Stefano  V,  Rinaldo  C,  Sacchi  A,  Soddu  S,  D’Orazi  G. 
Homeodomain‐interacting  protein  kinase‐2  activity  and  p53 
for  cisplatin‐mediated 
phosphorylation  are  critical  events 
apoptosis. Exp Cell Res. 2004; 293:311‐320. 
140.  Pistritto  G,  Puca  R,  Nardinocchi  L,  Sacchi  A,  D’Orazi  G. 
HIPK2‐induced  p53Ser46  phosphorylation 
the 
KILLER/DR5‐mediated  caspase‐8  extrinsic  apoptotic  pathway. 
Cell Death Diff. 2007; 14:1837‐1839. 
141. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D’Orazi 
G.  HIPK2  modulates  p53  activity  towards  pro‐apoptotic 
transcription. Mol Cancer. 2009; 8:85. 
142.  Garufi  A,  D'Orazi  G.  High  glucose  dephosphorylates  serine 
46 and inhibits p53 apoptotic activity. JECCR. 2014; 33:79. 
143.  Jin  ZG,  Shen  JF,  He  JY,  Hu  CQ.  Combination  therapy  with 
p53‐MDM2 binding inhibitors for malignancies. Med Chem Res. 
2015; 24:1369‐1379. 
144.  Vassilev  LT.  MDM2  inhibitors  for  cancer  therapy.  Trends 
Mol Med. 2007; 13:23‐31. 
145. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic 
Z,  Kong  N,  Kammlot  U,  Lukacs  C,  Klein  C,  Fotouhi  N,  Liu  EA.  In 

activates 

www.impactaging.com 

            617                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
the  p53  pathway  by  small‐molecule 

vivo  activation  of 
antagonists of MDM2. Science. 2004; 303:844‐848. 
146. Kojima K, Konopleva M, McQueen T, O’Brien S, Plunkett W, 
Andreeff  M.  Mdm2  inhibitor  Nutlin‐3a  induces  p53‐mediated 
apoptosis  by 
transcription‐
transcription‐dependent  and 
independent  mechanisms  that  may  overcome  Atm‐mediated 
resistance  to  fluodarabine  in  chronic  lymphocytic  leukemia. 
Blood 2006; 108:993‐1000. 
147.  Vaseva  AV  and  Moll  UM.  The  mitochondrial  p53  pathway. 
Biochim Biophys Acta. 2009; 1787: 414‐420. 
148.  Rinaldo  C,  Prodosmo  A,  Mancini  F,  Iacovelli  S,  Sacchi  A, 
Moretti  F,  Soddu  Silvia.  MDM2‐regulated  degradation  of  HIPK2 
prevents  p53Ser46  phosphorylation  and  DNA  damage‐induced 
apoptosis. Mol Cell. 2007; 25:739‐750. 
149.  Rinaldo  C,  Prodosmo  A,  Siepi  F,  Moncada  A,  Sacchi  A, 
Selivanova  G,  Soddu  S.  HIPK2  regulation  by  MDM2  determines 
tumor  cell  response  to  the  p53‐reactivating  drugs  Nutlin‐3  and 
RITA. Cancer Res. 2009; 69:6241–6248. 
150.  Nardinocchi  L,  Puca  R,  Givol  D,  D’Orazi  G.  Counteracting 
MDM2‐induced  HIPK2  downregulation  restores  the  HIPK2/p53 
apoptotic  signaling  in  cancer  cells.  FEBS  Lett.  2010;  584:4253‐
4258. 
151. Garufi A, Ubertini V, Mancini F, D’Orazi V, Baldari S, Moretti 
F, Bossi G, D’Orazi G. The beneficial effect of Zinc(II) on low‐dose 
chemotherapeutic sensitivity involves p53 activation in wild‐type 
p53‐carrying colorectal cancer cells JECCR. 2015; 34:87. 
152.  Nardinocchi  L,  Puca  R,  D'Orazi  G.  HIF‐1α  antagonizes  p53‐
mediated  apoptosis  by  triggering  HIPK2  degradation.  Aging 
(Albany NY). 2011; 3:33‐43. doi: 10.18632/aging.100254. 
IJ,  Schober  WD, 
153.  Kojima  K,  Konopleva  M,  Samudio 
Bornmann  WG,  Andreeff  M.  Concomitant  inhibition  of  MDM2 
and  Bcl‐2 protein  function  synergistically  induces  mitovhondrial 
apoptosis in AML. Cell Cycle 2006; 5:2778‐2786. 
154.  Wade  M,  Rodewald  LW,  Espinosa  JM,  Wahl  G.  BH3 
activation  blocks  Hdmx  suppression  of  apoptosis  and 
cooperates  with  Nutlin  to  induce  cell  death.  Cell  Cycle  2008; 
7:1973‐1982. 
155.  Zhao  YJ,  Aguilar  A,  Bernard  D,  Wang  S.  Small‐molecule 
inhibitors of the MDM2‐p53 protein‐protein interaction (MDM2 
Inhibitors)  in  clinical  trials  for  cancer  treatment.  J  Med  Chem. 
2015; 58:1038‐1052. 
156. Pellegrino M, Mancini F, Lucà R, Coletti A, Giacchè N, Manni 
I, Arisi I, Florenzano F, Teveroni E, Buttarelli M, Fici L, Brandi R, 
Bruno T, et al. Targeting the MDM2/MDM4 interaction interface 
as a promising approach for p53 reactivation. Cancer Res. 2015; 
75:4560‐4572. 
157.  Mancini  F,  Di Conza  G,  Pellegrino  M,  Rinaldo  C,  Prodosmo 
A,  Giglio  S,  D'Agnano  I,  Florenzano  F,  Felicioni  L,  Buttitta  F, 
Marchetti  A,  Sacchi  A,  Pontecorvi  A,  et  al.  MDM4  (MDMX) 
localizes  at  the  mitochondria  and  facilitates  the  p53‐mediated 
intrinsic‐apoptotic pathway. EMBO J. 2009; 28:1926‐1939. 
158.  Mancini  F,  Pieroni  L,  Monteleone  V,  Luca  R,  Fici  L,  Luca  E, 
Urbani  A,  Xiong  S,  Soddu  S,  Masetti  R,  Lozano  G,  Pontecorvi  A, 
Moretti  F.  MDM4/  HIPK2/p53  cytoplasmic  assembly  uncovers 
coordinated repression of molecules with anti‐apoptotic activity 
during  early  DNA  damage  response.  Oncogene.  2016;  35:228–
240. 
159.  Hoe  KK,  Verma  CS,  Lane  DP.  Drugging  the  p53  pathway: 
understanding the route to clinical efficacy. Nat Rev Drug Discov. 
2014; 13:217‐236. 

Selivanova  G. 

Zawancka‐Pankau, 

160. Yu X, Narayanan S, Vazquez A, Carpizo DR. Small molecule 
compounds  targeting  the  p53  pathway:  are  we  finally  making 
progress? Apoptosis. 2014; 19:1055‐1068. 
161. 
Pharmacological 
reactivation  of  p53  as  a  strategy  to  treat  cancer.  J  Intern  Med. 
2015; 277: 248‐259. 
162. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 
2012; 482:347‐355. 
163.  Lima  RT,  Busacca  S,  Almeida  GM,  Gaudino  G,  Fennell  DA, 
Helena  Vasconcelos  M  MicroRNA  regulation  of  core  apoptosis 
pathways in cancer. Eur J Cancer. 2011; 47:163‐174. 
164.  Huang  G,  Nishimoto  K,  Zhou  Z,  Hughes  D,  Kleinerman  ES. 
miR‐20a  encoded  by  the  miR‐17–92  cluster 
increases  the 
metastatic  potential  of  osteosarcoma  cells  by  regulating  Fas 
expression. Cancer Res. 2012; 72:908–916. 
165. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu 
L, Chen Z, Meng Z. The serum miR‐21 level serves as a predictor 
for  the  chemosensitivity  of  advanced  pancreatic  cancer,  and 
miR‐21  expression  confers  chemoresistance  by  targeting  FasL. 
Mol Oncol. 2013; 7:334–345. 
166. Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, 
Hyjek  E,  Zhang  J.  miR‐196b  directly  targets  both  HOXA9/MEIS1 
oncogenes  and  FAS  tumour  suppressor 
in  MLL‐rearranged 
leukaemia. Nat Commun. 2012; 2:688. 
167.  Shaffiey  F,  Cross  E,  Sathyanarayana  P.  Mir‐590  is  a  novel 
STAT5  regulated  oncogenic  miRNA  and  targets  FasL  in  acute 
myeloid leukemia. Blood. 2013; 122:3811–3811. 
168.  Guennewig  B,  Roos  M,  Dogar  AM,  Gebert  LF,  Zagalak  JA, 
Vongrad  V,  Metzner  KJ,  Hall  J.  Synthetic  pre‐microRNAs  reveal 
dual‐strand activity of miR‐34a on TNF‐α. RNA. 2014; 20:61–75. 
169. Zhang L, Dong L, Li Y, Hong Z, Wei W. The microRNA miR‐
181c  controls  microglia‐mediated  neuronal  apoptosis  by 
suppressing tumor necrosis factor. J Neuroinflamm. 2012; 9:211. 
170.  Rossato  M,  Curtale  G,  Tamassia  N,  Castellucci  M,  Mori  L, 
Gasperini S, Mariotti B, De Luca M, Mirolo M, Cassatella MA. IL‐
10‐induced  microRNA‐187  negatively  regulates  TNF‐α,  IL‐6,  and 
IL‐12p40  production  in  TLR4‐stimulated  monocytes.  Proc  Natl 
Acad Sci USA. 2012; 109:E3101–E3110. 
171. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui 
A,  Tatsumi  T,  Ishida  H,  Noda  T,  Nagano  H,  Doki  Y,  Mori  M, 
inhibits  Bcl‐xL 
let‐7  family  of  microRNAs 
Hayashi  N.  The 
expression  and  potentiates  sorafenib‐induced  apoptosis 
in 
human hepatocellular carcinoma. J Hepatol. 2010; 52:698‐704. 
172.  Sacconi  A,  Biagioni  F,  Canu  V,  Mori  F,  Di  Benedetto  A, 
Lorenzon  L,  Ercolani  C,  Di  Agostino  S,  Cambria  AM,  Germoni  S, 
Grasso G, Blandino R, Panebianco V, et al. miR‐204 targets Bcl‐2 
expression  and  enhances  responsiveness  of  gastric  cancer.  Cell 
Death Dis. 2012; 3:e423. 
173. Zhang Y, Schiff D, Park D, Abounader R. MicroRNA‐608 and 
MicroRNA‐34a  regulate  chordoma  malignancy  by  targeting 
EGFR, Bcl‐xL and MET. PloS ONE. 2014; 9:e91546. 
174. Kurataka O, Takahiro O. Genetic networks lead and follow 
tumor  development:  MicroRNA  regulation  of  cell  cycle  and 
apoptosis  in  the  p53  pathways.  Bio  Med  Res  Intern.  2014; 
2014:ID749724. 
175. Raver‐Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld 
N,  Moskovits  N,  Bentwich  Z,  Oren  M.  Transcriptional  activation 
of  miR‐34a  contributes  to  p53‐mediated  apoptosis.  Mol  Cell. 
2007; 26:731‐743. 
176.  Chang  TC,  Wentzel  EA,  Kent  OA,  Ramachandran  K, 
Mullendore  M,  Lee  KH,  Feldmann  G,  Yamakuchi  M,  Ferlito  M, 

www.impactaging.com 

            618                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
Lowenstein  CJ.  Transactivation  of  miR‐34a  by  p53  broadly 
influences  gene  expression  and  promotes  apoptosis.  Mol  Cell. 
2007; 26:745‐752. 
177.  Garibaldi  F,  Falcone  E,  Trisciuoglio  D,  Colombo  T,  Lisek  K, 
Walerych  D,  Del  Sal  G,  Paci  P,  Bossi  G,  Piaggio  G,  Gurtner  A. 
Mutant  p53  inhibits  miRNA  biogenesis  by  interfering  with  the 
microprocessor complex. Oncogene 2016. doi: 10.1038/onc.2016. 
51. [Epub ahead of print] 
178.  Baig  S,  Seevasant  I,  Mohamad  J,  Mukheem  A,  Huri  HZ, 
Kamarul  T.  Potential  of  apoptotic  pathway‐targeted  cancer 
thereapeutic  research:  Where  do  we  stand?  Cell  Death  Dis. 
2016; 7:e2058. 

www.impactaging.com 

           619                                          AGING, April 2016, Vol. 8 No.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
